普罗吉生物 Protgen
北京普罗吉生物科技发展有限公司 (Protgen Ltd.) 成立于 2004 年 8 月，是由留学归国人员创立的研发型高新技术企业。公司的研发及高层管理团队由多位留学欧美的资深学者和企业家组成，具有丰富的重组蛋白药物研发和生物技术公司管理运行经验。目前，公司员工本科以上学历达到 90% 以上，其中拥有博士和硕士学位的达 40% 以上。

普罗吉公司，是国家发展和改革委员会批准建立的 “抗肿瘤蛋白质药物国家工程实验室” 的共建单位，与清华大学有着密切合作，建立了高效和日趋成熟的产、学、研相结合的生物技术成果快速转化机制和模式。公司致力于研发具有自主知识产权和国际竞争力的重组蛋白质药物、抗体药物和肿瘤诊断试剂，在蛋白质药物规模化制备方面具有一系列国际领先的核心专有技术。

公司具有卓越的科研项目管理经验和先进的技术研发水平，承担并参与了多项国家级科研课题。“十五”期间公司参与完成国家 863 课题一项，目前正承担一项 863 课题，并参与一项 863 课题，主持“十一五”计划“重大新药创制”一项，参与“十一五”计划“重大新药创制”两项。公司已申请了五项 PCT 发明专利，分别进入四十一个国家和地区，其中一项已在中国获得授权。

长期以来，公司受到了北京市委、市政府，北京市科委及中关村管委会等部门的大力支持。公司首席科学家入选中央 2009 年度第一批“千人计划”；2010 年 4 月，公司荣获中关村国家自主创新示范区“2009 年重大科技成果产业化突出贡献单位”称号；同年，公司成为“北京生物医药产业跨越发展工程”（G20工程）第一批企业，并入选 2010 年中关村“瞪羚计划”首批重点培育企业。

公司力争在未来五年内，发挥重组蛋白规模化制备和蛋白质药物研发的优势，面向海内外生物医药市场，努力发展成为国内一流、国际知名的生物制药公司。


Protgen Ltd., as a new research high-technology company located in the Zhongguancun Science and Technology Park, was founded in August, 2004 by returned oversea scholars. The senior management team, who are in charge of the R & D and management, consist of several oversea scholars and enterprisers. At present, 90% employees of the company have bachelor degrees and 40% of them have doctoral degrees.

Located in the Zhongguancun Biomedical Park, Protgen Ltd. is the collaborator of the National Engineering Laboratory for Anti-tumor Protein Therapeutics authorized by the National Develop and Reform Commission. Protgen dedicates in developing recombinant protein drugs with intellectual property rights and international competitiveness, protein drugs, antibodies, diagnosis kits and service on recombinant proteins (protein purification, refolding; antibody preparation protein drug production).

Protgen believes efficiency, seriouseness, deploitation and innovation. According to our excellent project experience, Protgen has been participating many national science projects, such as 863, etc. Now Protgen has filed 4 PCT inventions and patents, one of which has been authorized in China.

Protgen is supported by many government departments. The chief scientist is selected to the “One-Thousand Talent Project”. On 23th April, Protgen is announced to be one of the G20 enterprises.

In the next five years, based on its advantages in protein science, Protgen will explore and seek for oversea market and make its best to become an internationally well-known biomedical company.